Trump and RFK Jr. make autism announcement as Tylenol maker and medical experts push back

President Trump made a controversial announcement regarding the use of acetaminophen during pregnancy, stating that the FDA believes it can be associated with an increased risk of autism. Despite the president’s claims, medical experts have maintained that acetaminophen is safe for use during pregnancy.

In response to the announcement, the FDA issued an open letter advising physicians to consider minimizing the use of acetaminophen for routine low-grade fevers during pregnancy. The agency emphasized that while studies have suggested a potential association between acetaminophen and adverse neurodevelopmental outcomes, a causal relationship has not been established.

Contrary to the president’s statements, a major study conducted in Sweden over 25 years found no evidence linking acetaminophen use during pregnancy to neurodevelopmental disorders in children. The FDA’s decision to caution against excessive acetaminophen use during pregnancy reflects the ongoing scientific debate surrounding this issue.

In light of these developments, Tylenol manufacturer, Kenvue, strongly refuted any claims linking acetaminophen to autism, citing independent scientific research that supports the safety of the drug during pregnancy. The company emphasized the importance of acetaminophen as a safe pain reliever option for expectant mothers, highlighting the potential risks associated with alternative medications.

Medical experts and organizations, including the American College of Obstetricians and Gynecologists and the Autism Science Foundation, have reiterated that acetaminophen is considered safe for use during pregnancy. While some previous studies have suggested a possible association between acetaminophen and neurodevelopmental disorders, larger and more robust studies have found no conclusive evidence to support this claim.

FDA Commissioner Marty Makary also announced the approval of leucovorin, a drug derived from folic acid, to treat autism in children. Leucovorin has shown promise in addressing certain autism cases, particularly those involving a defect in folate transport to the brain. While leucovorin is not a universal remedy for autism, it has the potential to benefit a significant percentage of children with the condition.

Overall, the debate surrounding acetaminophen use during pregnancy and its potential link to autism underscores the need for further research and evidence-based recommendations. It is essential for healthcare providers and expectant mothers to weigh the risks and benefits of medication use during pregnancy, taking into account the latest scientific findings and guidelines.